Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health ...

Boulder, CO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Healthy Gut, a Boulder-based digestive health company, announced the release of an updated formulation of its Holozyme product, reflecting the company’s ...

Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes. Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage ...

Dr Gupta will share how, with two products entering value-acceleration phase and an innovative pipeline poised to deliver the next generations of breakthrough medicines, Idorsia is on a path to ...

In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying ...

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported ...

“Regulatory flexibility must be tailored for cell and gene therapies,” said FDA Commissioner Marty Makary, M.D., M.P.H. “These are common-sense reforms that will address the unique characteristics of ...

SINGAPORE, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Health Information Sharing and Analysis Center (Health-ISAC) is pleased to announce the appointment of Paul Chua as its new Asia Pacific (APAC) Operations ...

Pivot to Growth Strategy Progress: Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative ...

Krish S. Krishnan, Chairman and Chief Executive Officer, and Suma M. Krishnan, President of Research and Development, will highlight these updates and Krystal’s strategic vision in a presentation at ...

Deliver on 2026 OJEMDA net product revenue guidance, with a focus on increasing persistency and driving new patient starts to support continued OJEMDA adoption as standard of care (SOC) in 2L ...

MBX plans to share the full 12-week dataset from Avail and one-year follow-up data at a medical conference in Q2 2026. An FDA End-of-Phase 2 meeting is planned for Q1 2026, as MBX continues to prepare ...